If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Maria Rita Castellani is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Guidelines on nuclear medicine imaging in neuroblastoma

Bar-Sever, Z., Biassoni, L., Shulkin, B., Kong, G., Hofman, M. S., Lopci, E., Manea, I., Koziorowski, J., Castellani, R., Boubaker, A., Lambert, B., Pfluger, T., Nadel, H., Sharp, S. & Giammarile, F., 2018, In : European Journal of Nuclear Medicine and Molecular Imaging. 45, 11, p. 2009-2024 16 p.

Research output: Contribution to journalArticle

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ladenstein, R., Pötschger, U., Valteau-Couanet, D., Luksch, R., Castel, V., Yaniv, I., Laureys, G., Brock, P., Michon, J. M., Owens, C., Trahair, T., Chan, G. C. F., Ruud, E., Schroeder, H., Beck Popovic, M., Schreier, G., Loibner, H., Ambros, P., Holmes, K., Castellani, M. R. & 4 others, Gaze, M. N., Garaventa, A., Pearson, A. D. J. & Lode, H. N., Dec 2018, In : The Lancet. Oncology. 19, 12, p. 1617-1629 13 p.

Research output: Contribution to journalArticle

  • Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1

    Yanik, G. A., Parisi, M. T., Naranjo, A., Nadel, H., Gelfand, M. J., Park, J. R., Ladenstein, R. L., Poetschger, U., Boubaker, A., Valteau-Couanet, D., Lambert, B., Castellani, M-R., Bar-Sever, Z., Oudoux, A., Kaminska, A., Kreissman, S. G., Shulkin, B. L. & Matthay, K. K., Mar 2018, In : Journal of Nuclear Medicine. 59, 3, p. 502-508 7 p.

    Research output: Contribution to journalArticle

  • Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials

    Ladenstein, R., Lambert, B., Pötschger, U., Castellani, M-R., Lewington, V., Bar-Sever, Z., Oudoux, A., Śliwińska, A., Taborska, K., Biassoni, L., Yanik, G. A., Naranjo, A., Parisi, M. T., Shulkin, B. L., Nadel, H., Gelfand, M. J., Matthay, K. K., Park, J. R., Kreissman, S. G., Valteau-Couanet, D. & 1 others, Boubaker, A., Feb 2018, In : European Journal of Nuclear Medicine and Molecular Imaging. 45, 2, p. 292-305 14 p.

    Research output: Contribution to journalArticle

  • 123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel.

    Lewington, V., Lambert, B., Poetschger, U., Sever, Z. B., Giammarile, F., McEwan, A. J. B., Castellani, R., Lynch, T., Shulkin, B. L., Drobics, M., Staudenherz, A. & Ladenstein, R., Feb 1 2017, In : European Journal of Pediatrics. 44, 2, p. 234-241 8 p.

    Research output: Contribution to journalArticle